pharma · Prostate Cancer · Hot Flush
Astellas Pharma GmbH
Astellas Pharma drug portfolio — 52 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 52 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Astellas Pharma drug portfolio — 52 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L02) compound in Astellas Pharma's portfolio. Molecular target: Androgen receptor.
US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.
US regulatory status: approved. Molecular target: Androgen receptor.
Sensory organs (S01) compound in Astellas Pharma's portfolio.
US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
US regulatory status: approved. Molecular target: Androgen receptor.
US regulatory status: approved.
US regulatory status: approved. Molecular target: DNA.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
US regulatory status: approved. Mechanism: Unknown.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Tubulin.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
Antineoplastic and immunomodulating agents (L01) compound in Astellas Pharma's portfolio. Molecular target: Nectin-4.
US regulatory status: approved. Molecular target: Androgen receptor.
US regulatory status: approved. Molecular target: Estrogen receptor.
US regulatory status: approved. Molecular target: Neuromedin-K receptor.
US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
Development asset linked to Astellas Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
Development asset linked to Astellas Pharma in public FDA and regional records.
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
Antineoplastic and immunomodulating agents (L01) compound in Astellas Pharma's portfolio. Molecular target: Receptor-type tyrosine-protein kinase FLT3.
Development asset linked to Astellas Pharma in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Beta-3 adrenergic receptor.
US regulatory status: approved. Molecular target: Programmed cell death protein 1.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Tubulin.
US regulatory status: approved. Molecular target: Programmed cell death protein 1.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
US regulatory status: approved.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
Development asset linked to Astellas Pharma in public FDA and regional records.
Development asset linked to Astellas Pharma in public FDA and regional records.
Antineoplastic and immunomodulating agents (L01) compound in Astellas Pharma's portfolio. Molecular target: Tubulin.
Antineoplastic and immunomodulating agents (L01) compound in Astellas Pharma's portfolio. Molecular target: Claudin-18.